首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Serum miR-125a-5p miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer
【2h】

Serum miR-125a-5p miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer

机译:血清miR-125a-5pmiR-145和miR-146a作为非小细胞肺癌的诊断生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Lung cancer is becoming the leading cause of cancer-related deaths with high mortality worldwide and in China as well. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer accounting for approximately 85% of all cases. Over 70% of cases are at loco-regionally advanced stages or have distant metastasis at the time of presentation with subsequently poor prognosis. MiRNAs are stable molecules in blood and used as biomarkers for the early diagnosis of various malignancy. The purpose of this study was to evaluate whether circulating miR-125a-5p, miR-145 and miR-146a could be used as biomarkers for the diagnosis of NSCLC through measuring their expression and assess their relationship with clinical pathological factors. Methods: Expression levels of serum miR-125a-5p, miR-145 and miR-146a were detected in 70 pairs of NSCLC patients and healthy controls using quantitative real-time PCR analysis. Results: Serum miR-125a-5p, miR-145 and miR-146a were overexpressed in NSCLC patients compared with healthy controls. Their values of the area under the receiver –operating characteristic curve (AUC-ROC) were 0.71, 0.84 and 0.78. Optimal sensitivity and specificity were 73.53% and 55.71%, 92.75% and 61.43%, 84.06% and 58.57%, respectively in differentiating NSCLC patients from healthy controls. Conclusions: These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
机译:背景:肺癌正在成为癌症相关死亡的主要原因,在世界范围内以及在中国,死亡率都很高。非小细胞肺癌(NSCLC)是最常见的肺癌类型,约占所有病例的85%。超过70%的病例处于局部晚期或出现时远处转移,预后较差。 MiRNA是血液中的稳定分子,可用作各种恶性肿瘤的早期诊断的生物标志物。这项研究的目的是通过测量其表达并评估其与临床病理因素的关系,评估循环miR-​​125a-5p,miR-145和miR-146a是否可以用作诊断NSCLC的生物标记。方法:采用实时荧光定量PCR技术检测70对NSCLC患者和健康对照组血清miR-125a-5p,miR-145和miR-146a的表达水平。结果:与健康对照组相比,NSCLC患者血清miR-125a-5p,miR-145和miR-146a过表达。接收器工作特性曲线(AUC-ROC)下的面积值分别为0.71、0.84和0.78。在区分NSCLC患者和健康对照者中,最佳敏感性和特异性分别为73.53%和55.71%,92.75%和61.43%,84.06%和58.57%。结论:这些初步数据表明,血清miR-125a-5p,miR-145和miR-146a可能是用于NSCLC临床诊断的有用的非侵入性生物标记物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号